Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Triprilumab + gemcitabine + cisplatin
- Development stage
- Unknown
- Lead developer
- Zhejiang University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy consists of Triprilumab, a monoclonal antibody targeting the programmed death-1 (PD-1) immune checkpoint, administered alongside the chemotherapy doublet gemcitabine and cisplatin. Developed by Zhejiang University, the regimen is being investigated for the treatment of advanced or unresectable intrahepatic cholangiocarcinoma. The addition of an immune checkpoint inhibitor to the standard-of-care chemotherapy backbone aims to enhance anti-tumor immune responses and improve clinical outcomes in patients with this aggressive biliary tract cancer. Triprilumab works by blocking the interaction between PD-1 on T cells and its ligands, thereby restoring the immune system's ability to recognize and attack cancer cells, while gemcitabine and cisplatin provide direct cytotoxic effects by inhibiting DNA synthesis and inducing DNA cross-linking.
- Other names
- Triprilumab + GPTriprilumab plus gemcitabine and cisplatinTriprilumab + Gemcitabine PLUS Cisplatin
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNA
Beyond the preview
Go deeper on Triprilumab + gemcitabine + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Triprilumab + gemcitabine + cisplatin.